Samsung Biologics Korea IPO may move ahead with potential delay of Samsung Bioepis US listing – sources
Risk aversion against biotech companies on Nasdaq could push back a KRW 2bn (USD 1.7bn) initial public offering of Samsung Bioepis, initially slated for the… Read More